• Kenvue recently reported stronger-than-expected Q4 and full-year 2025 results, with all three business segments returning to year-over-year growth for the first time since mid-2023 and management highlighting progress toward a potential value-creating combination with Kimberly‑Clark.
• The broad-based recovery across Self Care, Essential Health and Beauty underlines how execution on core priorities and portfolio balance is starting to reshape how investors assess Kenvue’s consumer health platform.
• With Q4 strength across all segments and progress toward a Kimberly‑Clark combination, we’ll now assess how this updates Kenvue’s investment narrative.

Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

Kenvue Investment Narrative Recap

To own Kenvue, you need to believe its broad consumer health portfolio can translate brand strength into consistent cash generation while it simplifies operations and executes on digital and innovation priorities. The latest Q4 beat and segment-wide return to growth support that execution angle and appear to reinforce, rather than change, the near term focus on operational streamlining as a key catalyst, while complexity, e commerce underdevelopment and ongoing strategic review still stand out as the biggest near term risks.

Among recent developments, the most directly relevant is Kenvue’s progress toward a potential combination with Kimberly Clark, called out alongside the Q4 2025 results and followed by multiple analyst price target increases. This potential deal sits squarely within the existing narrative of simplifying and refocusing the portfolio, and it could interact meaningfully with both the operational efficiency catalyst and the risk that restructuring and transition efforts create earnings volatility during execution.

Yet behind the improving quarterly numbers, investors should be aware of how Kenvue’s high internal complexity could still translate into...

Kenvue's narrative projects $16.3 billion revenue and $2.1 billion earnings by 2028. This implies 2.6% yearly revenue growth and about a $0.7 billion earnings increase from $1.4 billion today.

Uncover how Kenvue's forecasts yield a $19.83 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community see Kenvue’s fair value between US$19 and about US$29.98, highlighting a wide span of individual expectations. Set those against the recent all segment growth and Kimberly Clark discussions and you can start to see why it pays to weigh several different views on how execution risks might shape future performance.

Explore 4 other fair value estimates on Kenvue - why the stock might be worth as much as 71% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Kenvue research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Kenvue research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Kenvue's overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.